ArticleJACC. CardioOncology2023
ESC Cardio-Oncology Guidelines: A Triumph-But Are We Overscreening?
Article in JACC. CardioOncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Cardio-Oncological Sequelae of Autologous Stem Cell Transplantation: Role of Clonal Hematopoiesis in Cardiovascular Risk.JACC. Advances · 2026Article
- Cardiac Monitoring for Patients Undergoing Treatment With MEK Inhibitor Monotherapy.Current oncology reports · 2026Review
- An echocardiographic study of right ventricular function and pulmonary systolic pressure in patients treated with anthracyclines.Journal of cardiovascular imaging · 2026Article
- Applications, challenges and future directions of artificial intelligence in cardio-oncology.European journal of clinical investigation · 2025Review
- Quality-of-Care Measures for Cardio-Oncology: An IC-OS and ACC Cardio-Oncology Leadership Council Perspective.JACC. CardioOncology · 2025Review
- Macrotroponin interference and association with cardiotoxicity in patients receiving cardiotoxic breast cancer therapy: a pilot study.Cardio-oncology (London, England) · 2025Article
- Cardiovascular Considerations Before Cancer Therapy: Gaps in Evidence andJACC. CardioOncology · 2024Review
- PCSK9 Inhibitors and Anthracyclines: The Future of Cardioprotection in Cardio-Oncology.Hearts (Basel, Switzerland) · 2024Article
- Cardiology and oncology: a meeting of giants.Revista da Associacao Medica Brasileira (1992) · 2024Article
- Circulating Cardiovascular Biomarkers in Cancer Therapeutics-Related Cardiotoxicity: Review of Critical Challenges, Solutions, and Future Directions.Journal of the American Heart Association · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.